Enriching Preclinical Knowledge and Confidence With In Vivo Imaging

The introduction of small animal in vivo imaging tools in the 1990s offered the potential to: 1) expand pharmacologic knowledge preclinically, increasing confidence in understanding anatomical, functional, and molecular dynamics, and 2) conduct research of a more translational nature. The application of in vivo imaging in research and preclinical development is often referred to as pharmaco-imaging. For cancer, pharmaco-imaging has been largely focused on anatomic measurements, e.g., tumor growth/dissemination; although there are specific applications where pharmaco-imaging provides material information on mechanisms and molecular dynamics. In vivo imaging is also an extremely effective tool in assessing biologics biodistribution. MI Bioresearch (MI) believes the utility of in vivo imaging will continue to evolve and grow in the area of cancer, making access to in vivo imaging tools an important addition to the armamentarium available for interrogating pharmacology.

Outside of cancer, in vivo imaging has generated more utility, including cardiovascular disease, stroke, and a range of CNS disorders. MI is working on cutting-edge applications of pharmaco-imaging across many therapeutic areas.

For over a decade, MI has offered an industry-leading array of in vivo imaging modalities for optimum pharmacologic interrogation when needed.

MI provides imaging services in the following areas:

Because of the way MI is set up structurally, more than one imaging modality can be applied in a given study (multi-modal) to generate extremely robust or complementary datasets in the most economic manner possible.